- Home
- UONEK vs AKTX Comparison
UONEK vs AKTX Comparison
Compare UONEK & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UONEK
- AKTX
- Stock Information
- Founded
- UONEK 1980
- AKTX N/A
- Country
- UONEK United States
- AKTX United States
- Employees
- UONEK N/A
- AKTX N/A
- Industry
- UONEK Broadcasting
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- UONEK Consumer Discretionary
- AKTX Health Care
- Exchange
- UONEK Nasdaq
- AKTX Nasdaq
- Market Cap
- UONEK 22.8M
- AKTX 19.3M
- IPO Year
- UONEK N/A
- AKTX N/A
- Fundamental
- Price
- UONEK $0.49
- AKTX $0.51
- Analyst Decision
- UONEK
- AKTX Strong Buy
- Analyst Count
- UONEK 0
- AKTX 2
- Target Price
- UONEK N/A
- AKTX $3.30
- AVG Volume (30 Days)
- UONEK 107.2K
- AKTX 458.4K
- Earning Date
- UONEK 11-04-2025
- AKTX 11-13-2025
- Dividend Yield
- UONEK N/A
- AKTX N/A
- EPS Growth
- UONEK N/A
- AKTX N/A
- EPS
- UONEK N/A
- AKTX N/A
- Revenue
- UONEK $393,670,000.00
- AKTX N/A
- Revenue This Year
- UONEK N/A
- AKTX N/A
- Revenue Next Year
- UONEK N/A
- AKTX N/A
- P/E Ratio
- UONEK N/A
- AKTX N/A
- Revenue Growth
- UONEK N/A
- AKTX N/A
- 52 Week Low
- UONEK $0.44
- AKTX $0.50
- 52 Week High
- UONEK $1.40
- AKTX $2.45
- Technical
- Relative Strength Index (RSI)
- UONEK 35.31
- AKTX 30.19
- Support Level
- UONEK $0.46
- AKTX $0.60
- Resistance Level
- UONEK $0.52
- AKTX $0.65
- Average True Range (ATR)
- UONEK 0.05
- AKTX 0.07
- MACD
- UONEK -0.00
- AKTX -0.02
- Stochastic Oscillator
- UONEK 15.08
- AKTX 3.00
About UONEK Urban One Inc. Class D
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.